Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SGHTthis companySight Sciences, Inc.	$10.53	-10.72×	6.47×	5.35×	-11.05×	-82.2%	86.2%	-48.0%	-49.7%	-60.1%	-35.4%	-7.2%	0.64×	1.56×	-7.21×	10.22×	0.0%	4	1.35	1	C-
GKOSGlaukos Corporation	$235.47	-34.42×	9.84×	12.73×	-44.54×	-132.8%	77.5%	-17.1%	-37.0%	-28.6%	-10.6%	-0.8%	0.21×	-0.33×	-18.71×	4.69×	0.0%	4	31.48	1	C-
HROWHarrow Health, Inc.	$26.74	-350×	34.35×	6.61×	47×	-1507.5%	75.1%	14.2%	-1.9%	-9.8%	12.7%	2.4%	4.8×	4.25×	1.6×	2.2×	0.0%	4	1.85	1	C-
IRIXIRIDEX Corporation	$0.71	-4.5×	4.09×	0.38×	-6.57×	-928.4%	36.7%	-4.9%	-8.4%	-90.1%	-15.4%	-11.2%	0.92×	0.53×	0×	1.91×	0.0%	3	-2.54	2	C
OCULOcular Therapeutix, Inc.	$6.63	-8.55×	3.47×	43.86×	-6.47×	-101.4%	87.3%	-521.0%	-513.2%	-40.6%	-35.5%	-9.5%	0.12×	2.63×	-22.82×	15.39×	0.0%	2	2.82	1	C-
SGPSpyGlass Pharma, Inc. Common Stock	$37.41	-21.12×	-8.52×	0×	-19.05×	-91.4%	0.0%	0.0%	0.0%	40.3%	-38.6%	-4.0%	-0.02×	2.41×	0×	12.67×	0.0%	—	—	2	C
Peer median	—	-21.12×	4.09×	6.61×	-6.57×	-132.8%	75.1%	-4.9%	-8.4%	-28.6%	-15.4%	-4.0%	0.21×	2.41×	0×	4.69×	0.0%	4	2.33	1	—